ODP010 Relaxin Receptor RXFP1 Knockout in Adipose Tissue Progenitor Cells Results in Resistance to High Fat Diet-Induced Weigh Gain
Laboratory Study, published in J Endocr Soc (2022) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- J Endocr Soc (2022)
- Reported sample size
- —
- Source database
- Europe PMC
- PMCID
- PMC9624959
Abstract (original English)
Abstract Relaxin is a polypeptide hormone that signals through its cognate receptor RXFP1. Previous work demonstrated that global RXFP1-knockout mice developed age-related adipose tissue fibrosis and dysfunction. Our preliminary data suggested that adipose tissue progenitor cells (APC) express RXFP1 in the white adipose tissue in mice. To determine the role of APC in relaxin signaling, we crossed floxed RXFP1 mice (RXFP1-fl/fl) with mice expressing tamoxifen-inducible CRE recombinase under control of the platelet-derived growth factor receptor-β (PDGFRβ) promoter to produce conditional RXFP1 knockout in adipose tissue progenitor cells and fibroblasts (RXFP1-PKO). After tamoxifen treatment, both RXFP1-fl/fl and RXFP1-PKO mice were placed on a high fat diet (58% calories from fat) supplemented with sucrose and fructose in the drinking water, or chow diet for 16 weeks. At the end of the study, body mass composition was measured using an Echo-MRI instrument. Adipose tissue fibrosis was assessed histologically by Sirius red staining. In response to the HFD, the control (fl/fl) mice reached an average weight of 48.3 ± 0.6g, while the RXFP1-PKO mice were resistant to weight gain, reaching only 40.3 ±3g (p<. 05). The body mass composition changed in the RXFP1-fl/fl mice on HFD (34. 0% fat/55.2% lean) compared to chow (14.7% fat/68.9% lean). The RXFP1-PKO mice had a significantly lower
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.